GLP-1R Actions on Muscle and the Skeleton

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

April 1, 2026

Conditions
Musculoskeletal AbnormalitiesObesitySarcopenic ObesityOsteoporosisDrug Effect
Interventions
DRUG

Tirzepatide

GLP-1 based treatment for obesity

BEHAVIORAL

Lifestyle toolkit

2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.

Trial Locations (1)

70808

Robert L. Dubin, MD, Baton Rouge

All Listed Sponsors
lead

Pennington Biomedical Research Center

OTHER